CompletedPhase 3

Parasite Clearance and Protection From Infection (PCPI) in Cameroon

Cameroon902 participantsStarted 2024-06-10

Plain-language summary

The Cameroon PCPI study will measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP. The total number of participants is expected to be 900 healthy between 3 to 5 years old who have no symptoms of malaria infection of which 450 children will be assigned to the SP group, 250 to the SPAQ group, and 200 to the AS group. The results of this study will allow to measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP.

Who can participate

Age range3 Years – 5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be 3-5 years old * Exhibit no symptoms of malaria * Have parents/guardians willing to have their child participate in all follow-up visits and seek care from study staff * Reside in the study catchment area Exclusion Criteria: * Have evidence of acute illness as determined by clinical examination * Exhibit symptoms of malaria (axillary fever ≥ 37.5 °C and / or history of fever in past 48 hours) * Have known allergy to study medications * Have received antimalarial treatment or azithromycin within 28 days prior to screening * Be concomitantly receiving co-trimoxazole (trimethoprim-sulfamethoxazole) * Be categorised as severely malnourished according to WHO child growth standards

What they're measuring

Parasite clearance

Timeframe: 28 days (total follow up 63 days post SP dose)

Protection from infection

Timeframe: 28 days (total follow up 63 days post SP dose)

Trial details

NCT IDNCT06173206

SponsorLondon School of Hygiene and Tropical Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-25